Liberty Energy Inc. Class A common stock vs State Street SPDR S&P Biotech ETF — how do they compare? Liberty Energy Inc. Class A common stock trades at $19.08 (market cap $3.08B), while State Street SPDR S&P Biotech ETF trades at $153.7 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 3.3× Liberty Energy Inc. Class A common stock's market cap, and Liberty Energy Inc. Class A common stock pays a 1.91% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Energy Inc. Class A common stock for 1 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| LBRT | XBI | |
|---|---|---|
Market Cap | $3.08B | $10.11B |
Volume | 4,917,315 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $33.93 | $169.55 |
52-Week Low | $11.94 | $104.99 |
Typical Hold Time | 1 Days | 38 Days |
Enterprise Value | $4.13B | — |
Dividend Yield | 1.91% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Trailing returns across standard periods
Liberty Energy provides completion services and technologies for onshore oil, natural gas, and geothermal producers in North America. It also offers distributed power and energy-storage solutions through Liberty Power Innovations.
Read more on LBRT →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →